{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:49:52Z","timestamp":1785790192580,"version":"3.56.0"},"reference-count":24,"publisher":"Health Affairs Publishing, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Affairs"],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.1377\/hlthaff.2026.00209","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:55:37Z","timestamp":1785786937000},"page":"838-845","source":"Crossref","is-referenced-by-count":0,"title":["The Economics Of Orphan Blockbuster Drug Development"],"prefix":"10.1377","volume":"45","author":[{"given":"Jennifer C.","family":"Chen","sequence":"first","affiliation":[{"name":"Jennifer C. Chen, Verdant Research, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Madsen","sequence":"additional","affiliation":[{"name":"Chris Madsen, Verdant Research, Victoria, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kaltenboeck","sequence":"additional","affiliation":[{"name":"Anna Kaltenboeck (), Verdant Research, Oakton, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"102","reference":[{"key":"B1","unstructured":"IQVIA Institute. Orphan drugs in the United States (part one): growth trends in rare disease treatments [Internet]. Durham (NC): IQVIA; 2018 Oct 17 [cited 2026 Jun 18]. Available for download from: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/orphan-drugs-in-the-united-states-growth-trends-in-rare-disease-treatments"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01901-6"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00061-9"},{"key":"B4","unstructured":"Congressional Budget Office. Prescription drugs: spending, use, and prices [Internet]. Washington (DC): CBO; 2022 Jan [cited 2026 Jun 18]. (Report No.\u00a057772). Available from: https:\/\/www.cbo.gov\/publication\/57772"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.00595"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.01442"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.29006"},{"key":"B8","unstructured":"Swagel PL. Revised estimate of changes under the 2025 Reconciliation Act for exemptions from Medicare price negotiations for orphan drugs (letter to Honorable Frank Pallone Jr., Honorable Ron Wyden, and Honorable Richard E. Neal) [Internet]. Washington (DC): CBO; 2025 Oct 20 [cited 2026 Jun 18]. Available from: https:\/\/www.cbo.gov\/system\/files\/2025-10\/61818-Pallone-etal-orphan-drugs-letter-10-20-25.pdf"},{"key":"B9","unstructured":"Congressional Budget Office. Summary, estimated budgetary effects of Public Law 117-169, to provide for reconciliation pursuant to Title II of S. Con. Res. 14 [Internet]. Washington (DC): CBO; 2022 Sep 7 [cited 2026 Jun 18]. Available from: https:\/\/www.cbo.gov\/system\/files\/2022-09\/PL117-169_9-7-22.pdf"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1074512"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0990-4"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/0115701638379700250713040806"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-023-01639-x"},{"key":"B14","unstructured":"Lo AW, Thakor RT. Risk and reward in the orphan drug industry. Social Science Research Network [preprint on the Internet]. 2018 Sep 24 [cited 2026 Jun 18]. (MIT Sloan Research Paper No.\u00a05582-18). Available from: https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3254586"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02790-7"},{"key":"B16","unstructured":"Chen JC, Kaltenboeck A. The blockbuster orphan paradox: consequences of special treatment of rare disease drugs in Medicare negotiation. Health Affairs Forefront [blog on the Internet]. 2025 Aug 29 [cited 2026 Jun 18]. Available from: https:\/\/www.healthaffairs.org\/content\/forefront\/blockbuster-orphan-paradox-consequences-special-treatment-rare-disease-drugs-medicare"},{"key":"B17","unstructured":"Centers for Medicare and Medicaid Services. Medicare and Medicaid spending by drug [Internet]. Baltimore (MD): CMS; 2025 [cited 2026 Jun 18]. Available from: https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug"},{"key":"B18","unstructured":"Evaluate [home page on the Internet]. London: Evaluate Ltd.; c 2026 [cited 2026 Jun 18]. Available from: https:\/\/www.evaluate.com\/"},{"key":"B19","unstructured":"Food and Drug Administration. Drugs@FDA: FDA-approved drugs [Internet]. Silver Spring (MD): FDA; 2026 Apr [cited 2026 Jun 18]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"B20","unstructured":"Food and Drug Administration. Search orphan drug designations and approvals [Internet]. Silver Spring (MD): FDA; 2026 Apr [cited 2026 Jun 18]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/"},{"key":"B21","unstructured":"Federal Reserve Bank of St. Louis. Consumer Price Index for All Urban Consumers: medical care in U.S. city average (CPIMEDSL) [Internet]. St. Louis (MO): FRED; 2026 May [updated 2026 Jun 10; cited 2026 Jun 18]. Available from: https:\/\/fred.stlouisfed.org\/series\/CPIMEDSL"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2016.01.012"},{"key":"B23","unstructured":"Sertkaya A, Berger C. Drug development, final [Internet]. Washington (DC): Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation; 2024 Sep 26 [cited 2026 Jun 18]. Available from: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/ce102c41a7626cd885f7c88a9f2c4807\/drug-development.pdf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164681"}],"container-title":["Health Affairs"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:55:48Z","timestamp":1785786948000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.healthaffairs.org\/doi\/10.1377\/hlthaff.2026.00209"}},"subtitle":["Article examines the economics of orphan blockbuster drug development"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.1377\/hlthaff.2026.00209"],"URL":"https:\/\/doi.org\/10.1377\/hlthaff.2026.00209","relation":{},"ISSN":["0278-2715","1544-5208"],"issn-type":[{"value":"0278-2715","type":"print"},{"value":"1544-5208","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}